Curious to know which treatments are among the 15 bestselling most profitable drugs of all time? The pharmaceutical industry has been a topic of interest for investors, market...
Keep Reading →
November 24 - News
The top 10 largest pharmaceutical companies by revenue in 2017 are leading companies that have a large geographical presence, loyal customer base and technologically advanced ...
Keep Reading →
November 23 - News
Opus Point Partners was founded by Michael S. Weiss and Dr. Lindsay A. Rosenwald in 2009. Prior to launching Opus Point Partners, Mr. Weiss and Dr.
Keep Reading →
August 25 - Hedge Funds, News
"U.S. equities traded mostly lower on Friday as investors digested a tough week for retailers as well as mixed economic data.
Keep Reading →
May 12 - Commodities, Futures/Forex, Gold, Market Movers, News, Tech
Before we get to the list of 7 over-the-counter diet pills that work without exercise, we should ask ourselves if there exists such a thing. The short answer is no.
Keep Reading →
April 12 - Lists, News
AstraZeneca PLC (ADR) (NYSE:AZN) has acknowledged the receipt of the Complete Response Letter (CRL) from the U.S.
Keep Reading →
March 21 - News, Stock Analysis
In an effort to enhance collaboration with Circassia Pharmaceuticals, AstraZeneca PLC (ADR) (NYSE:AZN) has acquired an equity stake valued at $50 million in the respiratory biopharmaceutical...
Keep Reading →
March 20 - News, Stock Analysis
Lynparza, an ovarian cancer treatment developed by AstraZeneca PLC (ADR) (NYSE:AZN) has demonstrated its ability to slow down disease progression.
Keep Reading →
March 16 - News, Stock Analysis
It’s been a big week for PARP inhibitors.
Keep Reading →
March 15 - News, Stock Analysis
Are you interested in knowing the 7 Most Popular Diet Pills That Work Fast Without Exercise? I mean what better way to lose weight than to simply pop some pills and let the fat...
Keep Reading →
March 15 - Lists, News
AstraZeneca plc (ADR) (NYSE:AZN) is reconsidering some of its rejected drugs, as they could possess potential in curing a disease they were not initially meant to treat.
Keep Reading →
March 14 - News, Stock Analysis
Hutchison China MediTech Limited and AstraZeneca plc (ADR) (NYSE:AZN) are to present data from their phase II clinical trials of Savolitinib, at the upcoming 2017 Genitourinary...
Keep Reading →
February 15 - News, Stock Analysis
Trials of rival drugs from AstraZeneca PLC (ADR) (NYSE:AZN) and TESARO Inc (NASDAQ:TSRO) will determine the adoption of the PARP inhibitor, Rubraca from Clovis Oncology Inc (NASDAQ...
Keep Reading →
January 31 - News, Stock Analysis
The US Food and Drug Administration (FDA) has confirmed that Symbicort (budesonide/formoterol) Inhalation Aerosol is worth being granted paediatric exclusivity.
Keep Reading →
January 30 - News, Stock Analysis
AstraZeneca plc (ADR) (NYSE:AZN) share price could receive a major boost on the company pursuing a label expansion for its blockbuster Tagrisso.
Keep Reading →
January 3 - News, Stock Analysis
AstraZeneca plc (ADR) (NYSE:AZN)’s chief executive officer has said that the long negotiation process that the NHS undertakes with drugmakers before approving medications is...
Keep Reading →
December 30 - News, Stock Analysis
It takes a lot of guts for an individual to stand up against huge corporate entities for the overall well-being of the society.
Keep Reading →
December 30 - Lists, News
“By diligently prioritizing, we will continue to successfully launch and commercialize new medicines, meet the needs of our customers and patients, and ultimately help AstraZeneca...
Keep Reading →
December 9 - News, Stock Analysis
Tagrisso, a lung cancer med from AstraZeneca plc (ADR) (NYSE:AZN) is already in early approval based on mid-stage studies, which demonstrates the possibility of it replacing the...
Keep Reading →
December 7 - News, Stock Analysis
AstraZeneca plc (ADR) (NYSE:AZN) plans to cut some back office jobs in the U.K. as the company works toward cost-cutting and operation consolidation.
Keep Reading →
December 6 - News, Stock Analysis
The 1st US Circuit Court of Appeals has recently ruled in favor of AstraZeneca plc (ADR) (NYSE:AZN) and Ranbaxy Laboratories Limited (ADR) (OTCMKTS:RBXLY) on a long-lasting class...
Keep Reading →
November 23 - News, Stock Analysis
AstraZeneca PLC (ADR) (NYSE:AZN) will no longer seek early regulatory review of its drug candidate durvalumab in patients with head and neck cancers.
Keep Reading →
November 11 - Earnings Report, News, Stock Analysis
AstraZeneca plc (ADR) (NYSE:AZN) has recently released encouraging data from SOLO-2, a phase 3 clinical trial evaluating the efficacy of Lynparza (olaparib) as a monotherapy for...
Keep Reading →
October 27 - News, Stock Analysis
AstraZeneca Plc (ADR) (NYSE:AZN) has once again reiterated its intention to focus on core therapeutic areas with the signing of a new commercialization agreement with a subsidiary...
Keep Reading →
October 14 - News, Stock Analysis
Markets have opened at shaky note with major indices treading on margin.
Keep Reading →
October 4 - News
Therefore, in this article we will discuss Pandora Media Inc (NYSE:P), Trinity Biotech plc (ADR) (NASDAQ:TRIB), Seadrill Ltd (NYSE:SDRL), and Aralez Pharmaceuticals Inc (NASDAQ...
Keep Reading →
October 4 - News
It's a red day on Wall Street, as all three major indexes are off by around 0.35%, potentially due to some market participants remaining on the sidelines until the Deutsche Bank...
Keep Reading →
October 3 - Market Movers, News
In this article, we examine why five companies, Dollar General Corp.
Keep Reading →
August 31 - Earnings Report, News
Crude futures are below $42 per barrel this morning as traders brace for the upcoming rig count release on Friday.
Keep Reading →
July 28 - Market Movers, News
The Brexit is looming and, no matter how cute a name we can come up with, the issue is as serious as can be.
Keep Reading →
June 13 - Hedge Fund Analysis, Hedge Funds
The markets are off to a slow start today amid a report from the Labor Department which shows that over the last week, jobless claims surged to their highest levels in a year.
Keep Reading →
May 12 - Market Movers, News
With several major tech companies due to report earnings in the coming days, the NASDAQ and S&P 500 are strangely quiet.
Keep Reading →
April 26 - Market Movers, News
It's been an up-and-down day on Wall Street as the S&P 500 initially opened in the red before rallying to within a few percentage points of its all-time high.
Keep Reading →
April 18 - Market Movers, News
In the investing community, Tiger Cubs occupy a special spot, most of them becoming very successful hedge fund managers and delivering strong returns for their investors.
Keep Reading →
November 2 - Hedge Funds, News, Tech
Inovio Pharmaceuticals Inc (NASDAQ:INO) has spiked by over 29% on Monday morning after the firm announced a strategic cancer vaccine collaboration and license agreement with...
Keep Reading →
August 10 - Earnings Report, Hedge Funds, News
Investment professionals usually recommend a balanced portfolio of stocks and bonds, something like 60% stocks and 40% bonds.
Keep Reading →
March 27 - Hedge Funds, News
Jeremy Green’s Redmile Group entered several new positions last quarter, as revealed by the 13F Form it filed with the U.S. Securities and Exchange Commission in February.
Keep Reading →
March 2 - Hedge Funds, News
Two of our tracked funds have recently revealed in filings with the SEC that they’ve taken large new passive positions in a couple of stocks.
Keep Reading →
February 10 - Hedge Funds, News
Anders Hallberg and Carl Bennet’s HealthInvest Partners AB revealed its top picks for the fourth quarter of 2014. According to the 13F Form filed with the U.S.
Keep Reading →
January 25 - Hedge Funds, News
AstraZeneca plc (ADR) (NYSE:AZN) was considered somewhat of a dying flame two years ago, according to its CEO Pascal Soriot, but now the company is set for high paced development...
Keep Reading →
November 29 - News
The pharmaceutical industry was the focus of intense debate earlier this year owing to potential merger between Pfizer Inc. (NYSE:PFE) and AstraZeneca plc (ADR) (NYSE:AZN).
Keep Reading →
November 26 - News
Actavis plc (NYSE:ACT) is in hot water with the New York Attorney General’s office over practices they feel are manipulative of patients.
Keep Reading →
September 16 - News
Ranjith Gopinathan, who is a program manager, life sciences and healthcare practice at Frost & Sullivan during an interview on CNBC said that while Merck & Co., Inc.
Keep Reading →
July 29 - News
Hedge fund Elliott International has lifted its stake in German drugs distributor Celesio, bringing it close to a position where it could block the $8.3 billion takeover bid by...
Keep Reading →
November 26 - Hedge Funds
Every week Floating Path looks to highlight some of the crazier examples of HFT running amok in the markets.
Keep Reading →
September 16 - News
At the moment, there are dozens of gauges investors can use to track Mr. Market. A pair of the most under-the-radar are hedge fund and insider trading movement.
Keep Reading →
September 6 - News
Now, according to many investors, hedge funds are seen as overrated, outdated investment tools of a period lost to current times.
Keep Reading →
August 30 - News
In the eyes of many of your peers, hedge funds are perceived as useless, outdated financial tools of a forgotten age.
Keep Reading →
August 22 - News
Eli Lilly & Co. (NYSE:LLY) was in 35 hedge funds' portfolio at the end of March. LLY investors should be aware of a decrease in hedge fund interest recently.
Keep Reading →
August 13 - News